Legal & General Group
RNAC icon

Legal & General Group’s Cartesian Therapeutics RNAC Stock Holding History

Legal & General Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.63K Sell
915
-23
-2% -$164 ﹤0.01% 3270
2025
Q4 		$6.76K Hold
938
– – ﹤0.01% 3315
2025
Q3 		$9.59K Hold
938
– – ﹤0.01% 3291
2025
Q2 		$9.75K Sell
938
-212
-18% -$2.26K ﹤0.01% 3295
2025
Q1 		$15.2K Hold
1,150
– – ﹤0.01% 3044
2024
Q4 		$20.6K Buy
1,150
+349
+44% +$7.07K ﹤0.01% 3010
2024
Q3 		$12.9K Hold
801
– – ﹤0.01% 3210
2024
Q2 		$21.6K Buy
801
+413
+106% +$9.86K ﹤0.01% 2990
2024
Q1 		$7.56K Hold
388
– – ﹤0.01% 3254
2023
Q4 		$8.02K Hold
388
– – ﹤0.01% 3265
2023
Q3 		$12.4K Sell
388
-28
-7% -$935 ﹤0.01% 3222
2023
Q2 		$14K Buy
+416
New +$14.9K ﹤0.01% 3254
2022
Q2 		– Sell
-317
Closed -$12K – 3633
2022
Q1 		$12K Hold
317
– – ﹤0.01% 3368
2021
Q4 		$31K Hold
317
– – ﹤0.01% 3141
2021
Q3 		$40K Hold
317
– – ﹤0.01% 3040
2021
Q2 		$40K Buy
317
+89
+39% +$10.6K ﹤0.01% 3024
2021
Q1 		$31K Sell
228
-11
-5% -$1.37K ﹤0.01% 2980
2020
Q4 		$22K Hold
239
– – ﹤0.01% 3056
2020
Q3 		$18K Sell
239
-89
-27% -$6.82K ﹤0.01% 3007
2020
Q2 		$28K Buy
+328
New +$29.7K ﹤0.01% 2927
2019
Q3 		– Sell
-211
Closed -$11K – 3400
2019
Q2 		$11K Hold
211
– – ﹤0.01% 3345
2019
Q1 		$15K Buy
211
+122
+137% +$7.73K ﹤0.01% 3179
2018
Q4 		$7K Hold
89
– – ﹤0.01% 3310
2018
Q3 		$42K Hold
89
– – ﹤0.01% 2864
2018
Q2 		$36K Buy
89
+9
+11% +$3.19K ﹤0.01% 2917
2018
Q1 		$25K Sell
80
-31
-28% -$8.83K ﹤0.01% 3053
2017
Q4 		$33K Hold
111
– – ﹤0.01% 3017
2017
Q3 		$62K Buy
111
+53
+91% +$28.2K ﹤0.01% 2845
2017
Q2 		$34K Buy
58
+39
+205% +$17.2K ﹤0.01% 3007
2017
Q1 		$8K Hold
19
– – ﹤0.01% 3212
2016
Q4 		$10K Buy
+19
New +$11.1K ﹤0.01% 3210

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's RNAC Position: Q1 2026 in Review

Legal & General Group reduced its Cartesian Therapeutics (RNAC) stake by 2.5% in Q1 2026, selling an estimated $164 and leaving 915 shares worth $5.63K. The position accounts for ﹤0.01% of the portfolio, ranked #3270.

Legal & General Group first reported a position in RNAC in Q4 2016 and has held it in 31 quarters since. The position peaked at $62K in Q3 2017. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Legal & General Group held 915 shares of Cartesian Therapeutics worth $5.63K as of Q1 2026.
  • Legal & General Group sold 23 Cartesian Therapeutics shares in Q1 2026, an estimated $164.
  • Cartesian Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3270 holding.
  • Legal & General Group first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 31 quarters since.
  • Legal & General Group's Cartesian Therapeutics position peaked at $62K in Q3 2017.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.